Skip to main content Skip to main navigation menu Skip to site footer

Seroprevalence SARS-CoV-2 among the academic population of Universitas Gadjah Mada Yogyakarta

  • Osman Sianipar ,
  • Umi Solekhah Intansari ,
  • Tri Ratnaningsih ,
  • Arum Tri Wahyuningsih ,
  • Fuad Anshori ,
  • Alfin Harjuno Dwiputro ,
  • Adika Zhulhi Arjana ,


Background:  Many academicians in Yogyakarta, Indonesia, face the increased potential for Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) transmission in academic populations. Seroprevalence data can represent the number of infections showing the proportion of people exposed and those potentially immune to the virus and provide evidence for public health policymakers. The seroprevalence of SARS-CoV-2 in the academic population of Universitas Gadjah Mada (UGM) remains unknown, raising concerns about the immune status among the academic population. A cross-sectional study was conducted to estimate the seroprevalence rate of SARS-COV-2 infection in the UGM academic population.

Methods: We conducted a descriptive study of 406 subjects of the UGM academic population. In the cross-sectional analysis of data collected, we performed serological testing for SARS-COV-2 infection for random academicians willing to participate voluntarily. Subjects were categorized as high and low-risk based on SARS-CoV-2 exposure and work history. Data normality was tested with Kolmogorov-Smirnov test. Proportion differences were analyzed with chi-squared tests with a significance set as P<0.05.

Result: 406 subjects were included in this study, with most of the subjects (55.91%) being female. The majority of the subjects were students (82.27%). Most of the subjects were categorized as high-risk (51.72%). Eight subjects (1.97%) had reactive antibody testing. The prevalence of SARS-COV-2 infection was higher in the high-risk group than in the low-risk group (3.57% vs. 0.48%; p=0.01). The high-risk subjects had 7.5 times more incidence of reactive antibody results than low-risk subjects based on the prevalence ratio.

Conclusion: The seroprevalence of SARS-COV-2 immunity in the general academic population of the Universitas Gadjah Mada is 1.97%. These low proportions reflect that more strategies are needed to protect the high-risk group against SARS-CoV-2 exposure.


  1. World Health Organization (WHO). Corona Virus Disease (COVID-19) Situation Report-106. WHO. 2020.
  2. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 Antibody Seroprevalence in Santa Clara County, California. medRxiv. 2020;2020.04.14.20062463.
  3. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. medRxiv. 2020.
  4. Sutton D, Fuchs K, D’Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. N Engl J Med. 2020;
  5. Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, et al. T Cell Responses to Whole SARS Coronavirus in Humans. J Immunol. 2008;181(8):5490–500.
  6. Government begins large-scale virus infection and antibody test study. Department of Health and Social Care. 2020.
  7. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 -nCoV by RT-PCR. Euro Surveill. 2020;25(3):1–8.
  8. Yogyakarta Tanggap COVID-19 [Internet]. Available from:
  9. Farsalinos K, Poulas K, Kouretas D, Vantarakis A, Leotsinidis M, Kouvelas D, et al. Improved strategies to counter the COVID-19 pandemic: Lockdowns vs. Primary and Community Healthcare. Toxicol reports. 2020;8:1–9.
  10. Ariawan I, Jusril H. COVID-19 in Indonesia: Where Are We? Acta Med Indones. 2020;52(3):193–5.
  11. Andriani, S.Si, Apt, M.Sc, Ph.D H. Effectiveness of Large-Scale Social Restrictions (PSBB) toward the New Normal Era during COVID-19 Outbreak: a Mini Policy Review. J Indones Heal Policy Adm. 2020;5(2):61–5.
  12. Santini A. Optimising the assignment of swabs and reagent for PCR testing during a viral epidemic. Omega (United Kingdom). 2020;102(2):102341.
  13. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313–9.
  14. Lee CYP, Lin RTP, Renia L, Ng LFP. Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Front Immunol. 2020;11(April):1–7.
  15. Ho H-L, Wang F-Y, Lee H-R, Huang Y-L, Lai C-L, Jen W-C, et al. Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients. Lancet Reg Heal - West Pacific. 2020;3:100041.
  16. Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314–22.
  17. Dickson E, Palmateer NE, Murray J, Robertson C, Waugh C, Wallace LA, et al. Enhanced Surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Public Health. 2020;
  18. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2020;
  19. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. Jama. 2020;13:98–9.
  20. Xiang F, Wang X, He X, Peng Z, Yang B, Zhang J, et al. Antibody Detection and Dynamic Characteristics in Patients with Coronavirus Disease 2019. Clin Infect Dis. 2020;71(8):1930–4.
  21. Tan W, Lu Y, Zhang J, Wang J, Dan Y, Tan Z, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. 2020;
  22. Ikhsanudin A. Pemerintah Terbitkan Syarat Pengecualian Pembatasan Baru, Ini Bedanya [Internet]. detikNews. 2020. Available from:
  23. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and meta-analysis. J Hosp Infect. 2020;
  24. Venugopal U, Jilani N, Rabah S, Shariff MA, Jawed M, Mendez Batres A, et al. SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: A cross-sectional analysis during the COVID-19 pandemic. Int J Infect Dis. 2021;102:63–9.
  25. Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020;81(3):420–6.
  26. Varghese PM, Tsolaki AG, Yasmin H, Shastri A, Ferluga J, Vatish M, et al. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology. 2020;225(6):152008.
  27. Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we? Nat Rev Immunol. 2020;20(10):583–4.
  28. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020;52:737–41.
  29. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288(July):198114.
  30. Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2020;173751.

How to Cite

Sianipar, O., Intansari, U. S., Ratnaningsih, T., Wahyuningsih, A. T., Anshori, F., Dwiputro, A. H., & Arjana, A. Z. (2022). Seroprevalence SARS-CoV-2 among the academic population of Universitas Gadjah Mada Yogyakarta. Bali Medical Journal, 11(1), 382–386.




Search Panel

Osman Sianipar
Google Scholar
BMJ Journal

Umi Solekhah Intansari
Google Scholar
BMJ Journal

Tri Ratnaningsih
Google Scholar
BMJ Journal

Arum Tri Wahyuningsih
Google Scholar
BMJ Journal

Fuad Anshori
Google Scholar
BMJ Journal

Alfin Harjuno Dwiputro
Google Scholar
BMJ Journal

Adika Zhulhi Arjana
Google Scholar
BMJ Journal